Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Depreciation and Depletion (2018 - 2025)

IGC Pharma (IGC) has disclosed Depreciation and Depletion for 12 consecutive years, with $105000.0 as the latest value for Q3 2025.

  • Quarterly Depreciation and Depletion fell 27.59% to $105000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $512000.0 through Sep 2025, down 10.65% year-over-year, with the annual reading at $567000.0 for FY2025, 0.71% up from the prior year.
  • Depreciation and Depletion for Q3 2025 was $105000.0 at IGC Pharma, down from $127000.0 in the prior quarter.
  • The five-year high for Depreciation and Depletion was $200000.0 in Q1 2022, with the low at -$49000.0 in Q1 2023.
  • Average Depreciation and Depletion over 5 years is $135000.0, with a median of $144000.0 recorded in 2024.
  • The sharpest move saw Depreciation and Depletion tumbled 124.5% in 2023, then surged 397.96% in 2024.
  • Over 5 years, Depreciation and Depletion stood at $117000.0 in 2021, then skyrocketed by 35.04% to $158000.0 in 2022, then dropped by 11.39% to $140000.0 in 2023, then increased by 2.86% to $144000.0 in 2024, then decreased by 27.08% to $105000.0 in 2025.
  • According to Business Quant data, Depreciation and Depletion over the past three periods came in at $105000.0, $127000.0, and $136000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.